BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.
Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.
Conference Details:
Conference Date: Tuesday, November 12, 2024
Conference Time: 4:30 PM ET
Conference dial-in: 888-999-3182
International dial-in: 848-280-6330
Passcode: Xtant Medical Holdings
Conference Call Name: Xtant Medical Q3 2024 Financial Results
Webcast Link: https://www.webcaster4.com/Webcast/Page/3039/51623
Following the live call, a replay will be available on the Company's website, https://xtantmedical.com/, under "Investor Info."
About Xtant Medical Holdings, Inc.
Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (https://xtantmedical.com/) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Investor Relations Contact:
Brett Maas
Managing Partner
Hayden IR
This email address is being protected from spambots. You need JavaScript enabled to view it.
(646) 536-7331
| Last Trade: | US$0.74 |
| Daily Change: | 0.01 1.45 |
| Daily Volume: | 20,689 |
| Market Cap: | US$102.450M |
November 12, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
